Hepatocyte growth factor, a biomarker of macroangiopathy in diabetes mellitus

doi:10.4239/wjd.v5.i5.678

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 5, Issue 5

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7420)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-6) series.

Item

Count

PDF

505

WORD

297

HTML

4145

Figures (1-6)

275

Sum=5222

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1260

Download

938

Sum=2198

Oct 15, 2014 (publication date) through Nov 29, 2024

Times Cited of This Article

Times Cited (14)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Diabetes. Oct 15, 2014; 5(5): 678-688
Published online Oct 15, 2014. doi: 10.4239/wjd.v5.i5.678

Hepatocyte growth factor, a biomarker of macroangiopathy in diabetes mellitus

Hiroyuki Konya, Masayuki Miuchi, Kahori Satani, Satoshi Matsutani, Taku Tsunoda, Yuzo Yano, Tomoyuki Katsuno, Tomoya Hamaguchi, Jun-Ichiro Miyagawa, Mitsuyoshi Namba

Hiroyuki Konya, Satoshi Matsutani, Yuzo Yano, Department of Internal Medicine, Ashiya Municipal Hospital, Ashiya, Hyogo 659-8502, Japan

Masayuki Miuchi, Kahori Satani, Taku Tsunoda, Jun-Ichiro Miyagawa, Mitsuyoshi Namba, Division of Diabetes, Endocrinology and Metabolism, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501, Japan

Tomoyuki Katsuno, Division of Innovative Diabetes Treatment, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501, Japan

Tomoya Hamaguchi, Division of Diabetes, Department of Internal Medicine, Itami City Hospital, Itami, Hyogo 664-8540, Japan

Author contributions: Konya H and Namba M involved in collecting the required publications about the review and editing the manuscript; Konya H wrote the manuscript; all authors organized the structure of the review.

Correspondence to: Hiroyuki Konya, MD, PhD, Department of Internal Medicine, Ashiya Municipal Hospital, 39-1, Asahigaoka-cho, Ashiya, Hyogo 659-8502, Japan. h-dyer@mvi.biglobe.ne.jp

Telephone: +81-797-312156 Fax: +81-797-228822

Received: December 27, 2013
Revised: March 1, 2014
Accepted: May 31, 2014
Published online: October 15, 2014
Processing time: 233 Days and 10.7 Hours

Core Tip

Core tip: Hepatocyte growth factor (HGF) has been a mesenchymal-derived polyphenic factor which modulates development, motion, and morphosis of diverse cells, and has been regarded as a humor intermediator of epithelial-mesenchymal interplays. The serum levels of HGF in diabetes mellitus (DM) subjects might be assayed by balancing of stimulators (hypertension, atheromatous arteriosclerosis, etc.) and suppressors (hyperglycemia, transforming growth factor-, angiotensin II, etc.). The elevated serum level of HGF might have been regarded as an indicator of the DM involvements seriousness. Accordingly, the concentration of serum HGF might be a new and meaningful biomarker of macroangiopathy in DM subjects.